DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

Kizhakeyil, Atish; Zaini, Nurmahirah Binte Mohammed; Poh, Zhi Sheng; Wong, Brandon Han Siang; Loh, Xinpeng; Ng, Aik Seng; Low, Zun Siong; Prasannan, Praseetha; Gong, Chun; Tan, Michelle Guet Khim; Nagarajan, Chandramouli; Huang, Dachuan; Lu, Pang Wan; Lim, Jing Quan; Barrans, Sharon; Ong, Choon Kiat; Lim, Soon Thye; Chng, Wee Joo; Follows, George; Hodson, Daniel J; Du, Ming Qing; Goh, Yeow Tee; Tan, Suat Hoon; Grigoropoulos, Nicholas Francis; Verma, Navin Kumar

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

Published version

Peer-reviewed

Repository URI

https://www.repository.cam.ac.uk/handle/1810/330848

Repository DOI

https://doi.org/10.17863/CAM.78291

Files

Published version (3.73 MB)

Type

Other

Authors

Kizhakeyil, Atish

Zaini, Nurmahirah Binte Mohammed

Poh, Zhi Sheng

Wong, Brandon Han Siang

Loh, Xinpeng

Show 5 more

Description

Funder: addenbrooke's charitable trust, cambridge university hospitals

Keywords

Drug resistance, Prognosis, Tumour Metastasis, Hematolymphoid Malignancy, Ddx3x Mutation

Publisher DOI

https://doi.org/10.1186/s12943-021-01437-0

Rights

Attribution 4.0 International

Sponsorship

Wellcome Trust (203151/Z/16/Z)
medical research council (MR/M008584/1)
national medical research council (NMRC/TA/0051/2016, OFLCG18May-0028)
Cancer Research UK (A25117)
wellcome trust (203151/Z/16/Z)
nanyang technological university (L0412290)
kay kendall leukaemia fund (KKL649)
ministry of education - singapore (MOE2017-T2-2-004)
cancer research uk (A25117)
Medical Research Council (MR/M008584/1)

Collections

Jisc Publications Router